Preclinical evidence also supports the use of anti-PD-1/PD-L1 therapy for use with other BiTE formats, including BiTEs against Trop-2 [21] (commonly expressed in breast cancer), CEACAM5 [21], and GUCY2C [22] (expressed in colon cancers), CD33 [23] or FLT3 [24] for acute myeloid leukaemia (AML), gpA33 for colorectal cancer [25], an ImmTAC targeting NY-ESO-1 expressed in some non-small cell lung cancers [26]. Here, CD33 is linked to acute myeloid leukemia.